{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:12:29Z","timestamp":1790694749405,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009227","name":"Department of Medicine, University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013528","name":"Diabetes Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013528","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013739","name":"Pfizer Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ekir.2021.05.022","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T05:34:48Z","timestamp":1622871288000},"page":"2095-2104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes"],"prefix":"10.1016","volume":"6","author":[{"given":"Hongyan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas S.","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif Erik","family":"Lovblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Lytvyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davor","family":"Brinc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z.I.","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2021.05.022_bib1","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/j.2040-4603.2011.tb00365.x","article-title":"Pathophysiology of the diabetic kidney","volume":"1","author":"Vallon","year":"2011","journal-title":"Compr Physiol"},{"key":"10.1016\/j.ekir.2021.05.022_bib2","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2021.05.022_bib3","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2021.05.022_bib4","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2021.05.022_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2021.05.022_bib6","article-title":"Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review","volume":"17","author":"Rabizadeh","year":"2019","journal-title":"Int J Endocrinol Metab"},{"key":"10.1016\/j.ekir.2021.05.022_bib7","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of flycemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.05.022_bib8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.kint.2020.02.041","article-title":"The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?","volume":"98","author":"Hesp","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.05.022_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2021.05.022_bib10","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/jdi.13009","article-title":"Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats","volume":"10","author":"Kimura","year":"2019","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.ekir.2021.05.022_bib11","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2021.05.022_bib12","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2021.05.022_bib13","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1007\/s00125-013-2857-5","article-title":"The effect of renal hyperfiltration on urinary inflammatory cytokines\/chemokines in patients with uncomplicated type 1 diabetes mellitus","volume":"56","author":"Har","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2021.05.022_bib14","doi-asserted-by":"crossref","first-page":"e111131","DOI":"10.1371\/journal.pone.0111131","article-title":"The urinary cytokine\/chemokine signature of renal hyperfiltration in adolescents with type 1 diabetes","volume":"9","author":"Har","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2021.05.022_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186910","article-title":"The effect of sodium\/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome","volume":"12","author":"Cherney","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2021.05.022_bib16","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1007\/s00125-013-3000-3","article-title":"The effect of aliskiren on urinary cytokine\/chemokine responses to clamped hyperglycaemia in type 1 diabetes","volume":"56","author":"Cherney","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2021.05.022_bib17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00125-016-4190-2","article-title":"Assessment of urinary microparticles in normotensive patients with type 1 diabetes","volume":"60","author":"Lytvyn","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2021.05.022_bib18","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1681\/ASN.2018040368","article-title":"Platelet microparticles mediate glomerular endothelial injury in early diabetic nephropathy","volume":"29","author":"Zhang","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.05.022_bib19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/ki.2015.314","article-title":"Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes","volume":"89","author":"Nowak","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.05.022_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","article-title":"Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study","volume":"9","author":"Grunberger","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ekir.2021.05.022_bib21","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12882-019-1459-y","article-title":"Effect of hemodialysis on extracellular vesicles and circulating submicron particles","volume":"20","author":"Ruzicka","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2021.05.022_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2021.05.022_bib23","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2021.05.022_bib24","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2021.05.022_bib25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1210\/endrev\/bnz010","article-title":"The new biology of diabetic kidney disease-mechanisms and therapeutic implications","volume":"41","author":"Lytvyn","year":"2020","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ekir.2021.05.022_bib26","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1681\/ASN.2013070758","article-title":"Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes","volume":"25","author":"Sabbisetti","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.05.022_bib27","first-page":"1219","article-title":"Understanding kidney injury molecule 1: a novel immune factor in kidney pathophysiology","volume":"11","author":"Song","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.ekir.2021.05.022_bib28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/ki.2010.404","article-title":"Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-beta-D-glucosaminidase","volume":"79","author":"Vaidya","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.05.022_bib29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2337\/diab.43.5.629","article-title":"Increased renal metabolism in diabetes. Mechanism and functional implications","volume":"43","author":"Korner","year":"1994","journal-title":"Diabetes"},{"key":"10.1016\/j.ekir.2021.05.022_bib30","doi-asserted-by":"crossref","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","article-title":"Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats","volume":"309","author":"O'Neill","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ekir.2021.05.022_bib31","doi-asserted-by":"crossref","first-page":"14754","DOI":"10.1038\/s41598-019-51343-1","article-title":"Hypoxia-inducible factor-1alpha is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy","volume":"9","author":"Bessho","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2021.05.022_bib32","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.2337\/dc20-2265","article-title":"Changes in cardiovascular biomarkers associated with the sodium\u2013glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin in patients with chronic kidney disease and type 2 diabetes","volume":"44","author":"Lawler","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2021.05.022_bib33","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.kint.2018.05.026","article-title":"Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials","volume":"94","author":"Van Raalte","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.05.022_bib34","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2021.05.022_bib35","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12882-020-01960-0","article-title":"Renal expression of cytokines and chemokines in diabetic nephropathy","volume":"21","author":"Ara\u00fajo","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2021.05.022_bib36","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024921012055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024921012055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:38:05Z","timestamp":1762832285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024921012055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S2468024921012055"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2021.05.022","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2021.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2021.05.035","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}